117 results on '"Natowicz MR"'
Search Results
2. The use of medical records in research: what do patients want?
- Author
-
Kass NE, Natowicz MR, Hull SC, Faden RR, Plantinga L, Gostin LO, and Slutsman J
- Abstract
Despite growing policy interest in medical privacy, few empirical data reveal patients' views concerning use of medical records for research. Based on the authors' data and those of others, this article suggests guidelines regarding obtaining consent for the use of medical records in research that attempt to respect patient autonomy and promote scientific and medical uses of this information for the public good. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
3. A seat at the table: membership in federal advisory committees evaluating public policy in genetics.
- Author
-
Ard CF and Natowicz MR
- Abstract
OBJECTIVES: This study examined who participates in federal government advisory committees regarding public policy in human and medical genetics, what parties they represent, and to what extent the general public is meaningfully represented. METHODS: Analysis focused on 7 federal government documents published from January 1990 to February 1995. Advisors were categorized into 4 groups based on the professional affiliations that were listed in the publications. After a search of several references and data-bases, the study examined whether these individuals also had other affiliations not listed in the government publications. RESULTS: Individuals whose principal affiliations were with academia (n = 32; 44%) or industry (n = 19; 26%) represented nearly three fourths of the sample, followed by government employees (n = 13; 18%) and consumer advocates (n = 8; 11%). At least 16% of the advisors serving on the federal committees, mostly members of academia, had a dual affiliation. CONCLUSIONS: These data indicate that the public has modest representation on key federal advisory committees making policy recommendations regarding human genetics technology and clinical practice and that there is ample room for additional public participation. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
4. Public health policy forum. Public participation in medical policy-making and the status of consumer autonomy: the example of newborn-screening programs in the United States.
- Author
-
Hiller EH, Landenburger G, and Natowicz MR
- Abstract
OBJECTIVES: State newborn-screening programs collectively administer the largest genetic-testing initiative in the United States. We sought to assess public involvement in formulating and implementing medical policy in this important area of genetic medicine. METHODS: We surveyed all state newborn-screening programs to ascertain the screening tests performed, the mechanisms and extent of public participation, parental access to information, and policies addressing parental consent or refusal of newborn screening. We also reviewed the laws and regulations of each state pertaining to newborn screening. RESULTS: Only 26 of the 51 state newborn-screening programs reported having advisory committees that include consumer representation. Fifteen states reported having used institutional review boards, another venue for public input. The rights and roles of parents vary markedly among newborn-screening programs in terms of the type and availability of screening information as well as consent-refusal and follow-up policies. CONCLUSIONS: There is clear potential for greater public participation in newborn-screening policy-making. Greater public participation would result in more representative policy-making and could enhance the quality of services provided by newborn-screening programs. [ABSTRACT FROM AUTHOR]
- Published
- 1997
- Full Text
- View/download PDF
5. Late-onset Tay-Sachs disease: adverse effects of medications and implications for treatment.
- Author
-
Shapiro BE, Hatters-Friedman S, Fernandes-Filho JA, Anthony K, and Natowicz MR
- Published
- 2006
- Full Text
- View/download PDF
6. Late-onset Tay-Sachs disease presenting as a childhood stutter.
- Author
-
Shapiro BE, Natowicz MR, Shapiro, B E, and Natowicz, M R
- Published
- 2009
- Full Text
- View/download PDF
7. Numbers of prenatal cell-free DNA screens performed: Results of a 2022 CAP exercise.
- Author
-
Palomaki GE, Wyatt P, Rowsey R, Cacheris PM, Lepage N, Natowicz MR, Long T, and Moyer AM
- Subjects
- Humans, Female, Pregnancy, Prenatal Diagnosis methods, Prenatal Diagnosis statistics & numerical data, Trisomy diagnosis, Trisomy genetics, Maternal Serum Screening Tests statistics & numerical data, Maternal Serum Screening Tests methods, Cell-Free Nucleic Acids analysis, Cell-Free Nucleic Acids blood, Noninvasive Prenatal Testing methods, Noninvasive Prenatal Testing statistics & numerical data
- Abstract
Objective: Determine current analytical methods and number of cell-free (cf) DNA prenatal screening tests performed for common trisomies., Methods: The College of American Pathologists 2022-B Noninvasive Prenatal Testing exercise was distributed in December 2022 to 93 participants in 22 countries. Supplemental questions included the number of tests performed in a recent month and the proportion of samples originating outside the United States (US)., Results: Eighty-three participants from three continents returned results; 74 (89%) were suitable for the analyses. Nine manufacturer/platform combinations were identified, most commonly Illumina/Nextseq (55%). The most common methodology was whole genome sequencing (76%). Annualized cfDNA tests were 2.80 million, with Asian, European and North American participants representing 10.6%, 6.5% and 82.9% of tests, respectively. When restricted to US in-country tests, the annualized rate was 2.18 million, with four of 20 participants testing 79.2%. Among 73 respondents, 63 (86%) were for-profit, eight (11%) were non-profit academic or government supported and the remaining two included hospital-based and private non-profit. Eighteen (25%) supported relevant academic training., Conclusion: In 2011, screening for common trisomies was based on serum/ultrasound markers with an estimated 2.96 million US pregnancies screened in 131 laboratories. In 2022, cfDNA-based screening was offered by 20 laboratories testing 2.18 million US pregnancies., (© 2024 John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
8. Proteomic investigations of adult polyglucosan body disease: insights into the pathobiology of a neurodegenerative disorder.
- Author
-
Abraham JR, Allen FM, Barnard J, Schlatzer D, and Natowicz MR
- Abstract
Inadequate glycogen branching enzyme 1 (GBE1) activity results in different forms of glycogen storage disease type IV, including adult polyglucosan body disorder (APBD). APBD is clinically characterized by adult-onset development of progressive spasticity, neuropathy, and neurogenic bladder and is histologically characterized by the accumulation of structurally abnormal glycogen (polyglucosan bodies) in multiple cell types. How insufficient GBE1 activity causes the disease phenotype of APBD is poorly understood. We hypothesized that proteomic analysis of tissue from GBE1-deficient individuals would provide insights into GBE1-mediated pathobiology. In this discovery study, we utilized label-free LC-MS/MS to quantify the proteomes of lymphoblasts from 3 persons with APBD and 15 age- and gender-matched controls, with validation of the findings by targeted MS. There were 531 differentially expressed proteins out of 3,427 detected between APBD subjects vs. controls, including pronounced deficiency of GBE1. Bioinformatic analyses indicated multiple canonical pathways and protein-protein interaction networks to be statistically markedly enriched in APBD subjects, including: RNA processing/transport/translation, cell cycle control/replication, mTOR signaling, protein ubiquitination, unfolded protein and endoplasmic reticulum stress responses, glycolysis and cell death/apoptosis. Dysregulation of these processes, therefore, are primary or secondary factors in APBD pathobiology in this model system. Our findings further suggest that proteomic analysis of GBE1 mutant lymphoblasts can be leveraged as part of the screening for pharmaceutical agents for the treatment of APBD., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Abraham, Allen, Barnard, Schlatzer and Natowicz.)
- Published
- 2023
- Full Text
- View/download PDF
9. Metabolomic biomarkers in autism: identification of complex dysregulations of cellular bioenergetics.
- Author
-
Smith AM, Donley ELR, Ney DM, Amaral DG, Burrier RE, and Natowicz MR
- Abstract
Autism Spectrum Disorder (ASD or autism) is a phenotypically and etiologically heterogeneous condition. Identifying biomarkers of clinically significant metabolic subtypes of autism could improve understanding of its underlying pathophysiology and potentially lead to more targeted interventions. We hypothesized that the application of metabolite-based biomarker techniques using decision thresholds derived from quantitative measurements could identify autism-associated subpopulations. Metabolomic profiling was carried out in a case-control study of 499 autistic and 209 typically developing (TYP) children, ages 18-48 months, enrolled in the Children's Autism Metabolome Project (CAMP; ClinicalTrials.gov Identifier: NCT02548442). Fifty-four metabolites, associated with amino acid, organic acid, acylcarnitine and purine metabolism as well as microbiome-associated metabolites, were quantified using liquid chromatography-tandem mass spectrometry. Using quantitative thresholds, the concentrations of 4 metabolites and 149 ratios of metabolites were identified as biomarkers, each identifying subpopulations of 4.5-11% of the CAMP autistic population. A subset of 42 biomarkers could identify CAMP autistic individuals with 72% sensitivity and 90% specificity. Many participants were identified by several metabolic biomarkers. Using hierarchical clustering, 30 clusters of biomarkers were created based on participants' biomarker profiles. Metabolic changes associated with the clusters suggest that altered regulation of cellular metabolism, especially of mitochondrial bioenergetics, were common metabolic phenotypes in this cohort of autistic participants. Autism severity and cognitive and developmental impairment were associated with increased lactate, many lactate containing ratios, and the number of biomarker clusters a participant displayed. These studies provide evidence that metabolic phenotyping is feasible and that defined autistic subgroups can lead to enhanced understanding of the underlying pathophysiology and potentially suggest pathways for targeted metabolic treatments., Competing Interests: AS, ED, and RB are employees of Stemina Biomarker Discovery and are inventors on issued US Patent Nos. 10,060,932 and 11,268,966 entitled “Biomarkers of Autism Spectrum Disorder,” US Patent Application Serial No. 16/301044 entitled “Autism Subsets,” US Patent Application Serial No. 16/961995 entitled “Amino Acid Analysis and Autism Subsets,” US Patent Application Serial No. 17/608285 entitled “Diagnosis and Treatment of Autism Spectrum Disorders Associated With Altered Metabolic Pathways,” and US Patent Application Serial No. 17/768110 entitled “Diagnosis and Treatment of Autism Spectrum Disorders Using Altered Ratios of Metabolic Concentrations” and worldwide patent filings related to this work. MN, DN, and DA are members of the Stemina Biomarker Discovery, Inc. Scientific Advisory Board and have stock options., (Copyright © 2023 Smith, Donley, Ney, Amaral, Burrier and Natowicz.)
- Published
- 2023
- Full Text
- View/download PDF
10. A picture is worth a thousand words: A proposal to incorporate video into the evaluation of adults with intellectual or developmental disability living outside the home.
- Author
-
Prager BC, Broder SM, and Natowicz MR
- Subjects
- Adult, Child, Humans, Morbidity, Risk Factors, Developmental Disabilities, Intellectual Disability
- Abstract
Adults with intellectual or developmental disability (IDD) comprise 1-2% of the population worldwide. IDD is a significant risk factor for premature morbidity or mortality. This is likely due in part to preventable health conditions, which are modifiable with the intervention of direct care providers in areas including nutrition, promotion of an active lifestyle and effective identification of health or functional deterioration. Adults with IDD are also at increased risk for neglect or mistreatment, a finding that has been documented across multiple countries and in a variety of care settings. Contributing factors include resource availability, lack of person-centered care, management culture and care worker training. Practical and economical interventions may address the known disparities and challenges facing the large community of adults with IDD. To promote person-centered care, improve record-keeping/documentation, and aid in protecting the health and safety of this vulnerable population, we propose incorporation of a video into the evaluation of adults with IDD living outside the home., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Prager, Broder and Natowicz.)
- Published
- 2022
- Full Text
- View/download PDF
11. Climate Change and Medical Education: An Integrative Model.
- Author
-
Sullivan JK, Lowe KE, Gordon IO, Colbert CY, Salas RN, Bernstein A, Utech J, Natowicz MR, Mehta N, and Isaacson JH
- Subjects
- Models, Educational, Schools, Medical organization & administration, Climate Change, Curriculum, Education, Medical organization & administration
- Abstract
Medical schools face a challenge when trying to include new topics, such as climate change and health (CCH), in their curricula because of competing demands from more traditional biomedical content. At the same time, an understanding of CCH topics is crucial for physicians as they have clear implications for clinical practice and health care delivery. Although some medical schools have begun to incorporate CCH into curricula, the inclusion usually lacks a comprehensive framework for content and implementation. The authors propose a model for integrating CCH into medical school curricula using a practical, multistakeholder approach designed to mitigate competition for time with existing content by weaving meaningful CCH examples into current curricular activities. After the authors identified stakeholders to include in their curricular development working group, this working group determined the goals and desired outcomes of the curriculum; aligned those outcomes with the school's framework of educational objectives, competencies, and milestones; and strove to integrate CCH goals into as many existing curricular settings as possible. This article includes an illustration of the proposed model for one of the curricular goals (understanding the impacts of climate change on communities), with examples from the CCH curriculum integration that began in the fall of 2020 at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The authors have found that this approach does minimize competition for time with existing content and allows mapping of content to existing curricular competencies and milestones, while encouraging a broad understanding of CCH in the context of individual patients, populations, and communities. This model for curricular integration can be applied to other topics such as social determinants of health, health equity, disability studies, and structural racism., (Copyright © 2021 by the Association of American Medical Colleges.)
- Published
- 2022
- Full Text
- View/download PDF
12. De Novo Variants in the ATPase Module of MORC2 Cause a Neurodevelopmental Disorder with Growth Retardation and Variable Craniofacial Dysmorphism.
- Author
-
Guillen Sacoto MJ, Tchasovnikarova IA, Torti E, Forster C, Andrew EH, Anselm I, Baranano KW, Briere LC, Cohen JS, Craigen WJ, Cytrynbaum C, Ekhilevitch N, Elrick MJ, Fatemi A, Fraser JL, Gallagher RC, Guerin A, Haynes D, High FA, Inglese CN, Kiss C, Koenig MK, Krier J, Lindstrom K, Marble M, Meddaugh H, Moran ES, Morel CF, Mu W, Muller EA 2nd, Nance J, Natowicz MR, Numis AL, Ostrem B, Pappas J, Stafstrom CE, Streff H, Sweetser DA, Szybowska M, Walker MA, Wang W, Weiss K, Weksberg R, Wheeler PG, Yoon G, Kingston RE, and Juusola J
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Female, Genetic Diseases, Inborn genetics, Heterozygote, Humans, Infant, Intellectual Disability genetics, Male, Microcephaly genetics, Middle Aged, Phenotype, Young Adult, Adenosine Triphosphatases genetics, Craniofacial Abnormalities genetics, Growth Disorders genetics, Mutation genetics, Neurodevelopmental Disorders genetics, Transcription Factors genetics
- Abstract
MORC2 encodes an ATPase that plays a role in chromatin remodeling, DNA repair, and transcriptional regulation. Heterozygous variants in MORC2 have been reported in individuals with autosomal-dominant Charcot-Marie-Tooth disease type 2Z and spinal muscular atrophy, and the onset of symptoms ranges from infancy to the second decade of life. Here, we present a cohort of 20 individuals referred for exome sequencing who harbor pathogenic variants in the ATPase module of MORC2. Individuals presented with a similar phenotype consisting of developmental delay, intellectual disability, growth retardation, microcephaly, and variable craniofacial dysmorphism. Weakness, hyporeflexia, and electrophysiologic abnormalities suggestive of neuropathy were frequently observed but were not the predominant feature. Five of 18 individuals for whom brain imaging was available had lesions reminiscent of those observed in Leigh syndrome, and five of six individuals who had dilated eye exams had retinal pigmentary abnormalities. Functional assays revealed that these MORC2 variants result in hyperactivation of epigenetic silencing by the HUSH complex, supporting their pathogenicity. The described set of morphological, growth, developmental, and neurological findings and medical concerns expands the spectrum of genetic disorders resulting from pathogenic variants in MORC2., (Copyright © 2020 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
13. A Metabolomics Approach to Screening for Autism Risk in the Children's Autism Metabolome Project.
- Author
-
Smith AM, Natowicz MR, Braas D, Ludwig MA, Ney DM, Donley ELR, Burrier RE, and Amaral DG
- Subjects
- Biomarkers blood, Child, Preschool, Early Diagnosis, Glycine, Humans, Infant, Male, Mass Screening methods, Metabolome, Reproducibility of Results, Risk, Autism Spectrum Disorder diagnosis, Autism Spectrum Disorder epidemiology, Metabolomics methods
- Abstract
Autism spectrum disorder (ASD) is biologically and behaviorally heterogeneous. Delayed diagnosis of ASD is common and problematic. The complexity of ASD and the low sensitivity of available screening tools are key factors in delayed diagnosis. Identification of biomarkers that reduce complexity through stratification into reliable subpopulations can assist in earlier diagnosis, provide insight into the biology of ASD, and potentially suggest targeted interventions. Quantitative metabolomic analysis was performed on plasma samples from 708 fasting children, aged 18 to 48 months, enrolled in the Children's Autism Metabolome Project (CAMP). The primary goal was to identify alterations in metabolism helpful in stratifying ASD subjects into subpopulations with shared metabolic phenotypes (i.e., metabotypes). Metabotypes associated with ASD were identified in a discovery set of 357 subjects. The reproducibility of the metabotypes was validated in an independent replication set of 351 CAMP subjects. Thirty-four candidate metabotypes that differentiated subsets of ASD from typically developing participants were identified with sensitivity of at least 5% and specificity greater than 95%. The 34 metabotypes formed six metabolic clusters based on ratios of either lactate or pyruvate, succinate, glycine, ornithine, 4-hydroxyproline, or α-ketoglutarate with other metabolites. Optimization of a subset of new and previously defined metabotypes into a screening battery resulted in 53% sensitivity (95% confidence interval [CI], 48%-57%) and 91% specificity (95% CI, 86%-94%). Thus, our metabolomic screening tool detects more than 50% of the autistic participants in the CAMP study. Further development of this metabolomic screening approach may facilitate earlier referral and diagnosis of ASD and, ultimately, more targeted treatments. LAY SUMMARY: Analysis of a selected set of metabolites in blood samples from children with autism and typically developing children identified reproducible differences in the metabolism of about half of the children with autism. Testing for these differences in blood samples can be used to help screen children as young as 18 months for risk of autism that, in turn, can facilitate earlier diagnoses. In addition, differences may lead to biological insights that produce more precise treatment options. We are exploring other blood-based molecules to determine if still a higher percentage of children with autism can be detected using this strategy. Autism Res 2020, 13: 1270-1285. © 2020 The Authors. Autism Research published by International Society for Autism Research published by Wiley Periodicals LLC., (© 2020 The Authors. Autism Research published by International Society for Autism Research published by Wiley Periodicals LLC.)
- Published
- 2020
- Full Text
- View/download PDF
14. Editorial: Secondary vs. Idiopathic Autism.
- Author
-
Casanova MF, Casanova EL, Frye RE, Baeza-Velasco C, LaSalle JM, Hagerman RJ, Scherer SW, and Natowicz MR
- Published
- 2020
- Full Text
- View/download PDF
15. Proteomic Investigations of Autism Brain Identify Known and Novel Pathogenetic Processes.
- Author
-
Abraham JR, Szoko N, Barnard J, Rubin RA, Schlatzer D, Lundberg K, Li X, and Natowicz MR
- Subjects
- Autistic Disorder metabolism, Brain metabolism, Case-Control Studies, Cerebral Cortex metabolism, Humans, Occipital Lobe metabolism, Autistic Disorder pathology, Brain pathology, Cerebral Cortex pathology, Occipital Lobe pathology, Protein Interaction Maps, Proteome analysis, Proteome metabolism
- Abstract
Autism Spectrum Disorder (ASD) is a set of heterogeneous neurodevelopmental conditions defined by impairments in social communication and restricted, repetitive behaviors, interests or activities. Only a minority of ASD cases are determined to have a definitive etiology and the pathogenesis of most ASD is poorly understood. We hypothesized that a global analysis of the proteomes of human ASD vs. control brain, heretofore not done, would provide important data with which to better understand the underlying neurobiology of autism. In this study, we characterized the proteomes of two brain regions, Brodmann area 19 (BA19) and posterior inferior cerebellum (CB), from carefully selected idiopathic ASD cases and matched controls using label-free HPLC-tandem mass spectrometry. The data revealed marked differences between ASD and control brain proteomes for both brain regions. Unlike earlier transcriptomic analyses using frontal and temporal cortex, however, our proteomic analysis did not support ASD attenuating regional gene expression differences. Bioinformatic analyses of the differentially expressed proteins between cases and controls highlighted canonical pathways involving glutamate receptor signaling and glutathione-mediated detoxification in both BA19 and CB; other pathways such as Sertoli cell signaling and fatty acid oxidation were specifically enriched in BA19 or CB, respectively. Network analysis of both regions of ASD brain showed up-regulation of multiple pre- and post-synaptic membrane or scaffolding proteins including glutamatergic ion channels and related proteins, up-regulation of proteins involved in intracellular calcium signaling, and down-regulation of neurofilament proteins, with DLG4 and MAPT as major hub proteins in BA19 and CB protein interaction networks, respectively. Upstream regulator analysis suggests neurodegeneration-associated proteins drive the differential protein expression for ASD in both BA19 and CB. Overall, the proteomic data provide support for shared dysregulated pathways and upstream regulators for two brain regions in human ASD brain, suggesting a common ASD pathophysiology that has distinctive regional expression.
- Published
- 2019
- Full Text
- View/download PDF
16. Proteomic investigations of human HERC2 mutants: Insights into the pathobiology of a neurodevelopmental disorder.
- Author
-
Abraham JR, Barnard J, Wang H, Noritz GH, Yeganeh M, Buhas D, and Natowicz MR
- Subjects
- Adult, Autistic Disorder genetics, Autistic Disorder metabolism, Case-Control Studies, Child, Female, Gene Expression Regulation, Guanine Nucleotide Exchange Factors chemistry, Homozygote, Humans, Intellectual Disability genetics, Intellectual Disability metabolism, Male, Middle Aged, Mutation, Missense, Protein Interaction Maps, Proteomics, Signal Transduction, Syndrome, Ubiquitin-Protein Ligases, Young Adult, Guanine Nucleotide Exchange Factors genetics, Guanine Nucleotide Exchange Factors metabolism, Neurodevelopmental Disorders genetics, Neurodevelopmental Disorders metabolism
- Abstract
HERC2 is a giant protein with E3 ubiquitin ligase activity and other known and suspected functions. Mutations of HERC2 are implicated in the pathogenesis of various cancers and result in severe neurological conditions in Herc2-mutant mice. Recently, a pleotropic autosomal recessive HERC2-associated syndrome of intellectual disability, autism and variable neurological deficits was described; its pathogenetic basis is largely unknown. Using peripheral blood-derived lymphoblasts from 3 persons with homozygous HERC2 variants and 14 age- and gender-matched controls, we performed label-free unbiased HPLC-tandem mass spectrometry-based proteomic analyses to provide insights into HERC2-mediated pathobiology. We found that out of 3427 detected proteins, there were 812 differentially expressed proteins between HERC2-cases vs. controls. 184 canonical pathways were enriched after FDR adjustment, including mitochondrial function, energy metabolism, EIF2 signaling, immune functions, ubiquitination and DNA repair. Ingenuity Pathway Analysis
® identified 209 upstream regulators that could drive the differential expression, prominent amongst which were neurodegeneration-associated proteins. Differentially expressed protein interaction networks highlighted themes of immune function/dysfunction, regulation of cell cycle/cell death, and energy metabolism. Overall, the analysis of the HERC2-associated proteome revealed striking differential protein expression between cases and controls. The large number of differentially expressed proteins likely reflects HERC2's multiple domains and numerous interacting proteins. Our canonical pathway and protein interaction network findings suggest derangements of multiple pathways in HERC2-associated disease., (Copyright © 2019 Elsevier Inc. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
17. Proteomic Investigations of Autism Spectrum Disorder: Past Findings, Current Challenges, and Future Prospects.
- Author
-
Abraham J, Szoko N, and Natowicz MR
- Subjects
- Humans, Autism Spectrum Disorder diagnosis, Biomarkers, Proteomics
- Abstract
Proteomics is a powerful tool to study biological systems and is potentially useful in identifying biomarkers for clinical screening and diagnosis, for monitoring treatment, and for exploring pathogenetic mechanisms in autism. Unlike numerous other experimental approaches employed in autism research, there have been few proteomic-based analyses. Herein, we discuss the findings of studies regarding autism that utilized a proteomic approach and review key considerations in sample acquisition, processing, and analysis. Most proteomic studies on autism used blood or other peripheral tissues. Few studies used brain tissue, the main site of biological difference between persons with autism and others. The findings have varied and are not yet replicated. Some showed abnormalities of synaptic proteins or proteins of mitochondrial bioenergetics. Various abnormalities of proteins relating to immune processes and lipid metabolism have also been noted. Whether any of the proteomic differences between autism and control cases are primary or secondary phenomena is currently unclear. Consequently, no definitive biomarkers for autism have been identified, and the pathophysiological insights provided by proteomic studies to date are uncertain in the absence of replication. Based on this body of work and the challenges in using proteomics to study autism, we suggest considerations for future study design. These include attention to subject and specimen inclusion/exclusion criteria, attention to the state of specimens prior to proteomic analysis, and use of a replicate set of specimens. We end by discussing especially promising applications of proteomics in the study of autism pathobiology.
- Published
- 2019
- Full Text
- View/download PDF
18. The accuracy of computer-based diagnostic tools for the identification of concurrent genetic disorders.
- Author
-
Wadhwa RR, Park DY, and Natowicz MR
- Subjects
- Child, Preschool, Computational Biology methods, Diagnosis, Computer-Assisted standards, Diagnosis, Differential, Genetic Testing standards, Humans, Male, Reproducibility of Results, Sensitivity and Specificity, Software, Web Browser, Diagnosis, Computer-Assisted methods, Genetic Diseases, Inborn diagnosis, Genetic Diseases, Inborn genetics, Genetic Testing methods
- Abstract
The increasing use of next-generation sequencing, especially clinical exome sequencing, has revealed that individuals having two coexisting genetic conditions are not uncommon occurrences. This pilot study evaluates the efficacy of two methodologically distinct computational differential diagnosis generating tools-FindZebra and SimulConsult-in identifying multiple genetic conditions in a single patient. Clinical query terms were generated for each of 15 monogenic disorders that were effective in resulting in the top 10 list of differential diagnoses for each of the 15 monogenic conditions when entered into these bioinformatics tools. Then, the terms of over 125 pairings of these conditions were entered using each tool and the resulting list of diagnoses evaluated to determine how often both diagnoses of a pair were represented in that list. Neither tool was successful in identifying both members of a pair of conditions in greater than 40% of test cases. Disorder detection sensitivity was not homogeneous within a tool, with each tool favoring the identification of a subset of genetic conditions. In view of recent exome sequencing data showing an unexpectedly high prevalence of coexistent monogenic conditions, the results from this pilot study highlight a need for the development of computational tools designed to effectively generate differential diagnoses with consideration of the possibility of coexisting conditions., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
19. Metabolomic analysis of obesity, metabolic syndrome, and type 2 diabetes: amino acid and acylcarnitine levels change along a spectrum of metabolic wellness.
- Author
-
Libert DM, Nowacki AS, and Natowicz MR
- Abstract
Background: Metabolic syndrome (MS) is a construct used to separate "healthy" from "unhealthy" obese patients, and is a major risk factor for type 2 diabetes (T2D) and cardiovascular disease. There is controversy over whether obese "metabolically well" persons have a higher morbidity and mortality than lean counterparts, suggesting that MS criteria do not completely describe physiologic risk factors or consequences of obesity. We hypothesized that metabolomic analysis of plasma would distinguish obese individuals with and without MS and T2D along a spectrum of obesity-associated metabolic derangements, supporting metabolomic analysis as a tool for a more detailed assessment of metabolic wellness than currently used MS criteria., Methods: Fasting plasma samples from 90 adults were assigned to groups based on BMI and ATP III criteria for MS: (1) lean metabolically well (LMW; n = 24); (2) obese metabolically well (OBMW; n = 26); (3) obese metabolically unwell (OBMUW; n = 20); and (4) obese metabolically unwell with T2D (OBDM; n = 20). Forty-one amino acids/dipeptides, 33 acylcarnitines and 21 ratios were measured. Obesity and T2D effects were analyzed by Wilcoxon rank-sum tests comparing obese nondiabetics vs LMW, and OBDM vs nondiabetics, respectively. Metabolic unwellness was analyzed by Jonckheere-Terpstra trend tests, assuming worsening health from LMW → OBMW → OBMUW. To adjust for multiple comparisons, statistical significance was set at p < 0.005. K-means cluster analysis of aggregated amino acid and acylcarnitine data was also performed., Results: Analytes and ratios significantly increasing in obesity, T2D, and with worsening health include: branched-chain amino acids (BCAAs), cystine, alpha-aminoadipic acid, phenylalanine, leucine + lysine, and short-chain acylcarnitines/total carnitines. Tyrosine, alanine and propionylcarnitine increase with obesity and metabolic unwellness. Asparagine and the tryptophan/large neutral amino acid ratio decrease with T2D and metabolic unwellness. Malonylcarnitine decreases in obesity and 3-OHbutyrylcarnitine increases in T2D; neither correlates with unwellness. Cluster analysis did not separate subjects into discreet groups based on metabolic wellness., Discussion: Levels of 15 species and metabolite ratios trend significantly with worsening metabolic health; some are newly recognized. BCAAs, aromatic amino acids, lysine, and its metabolite, alpha-aminoadipate, increase with worsening health. The lysine pathway is distinct from BCAA metabolism, indicating that biochemical derangements associated with MS involve pathways besides those affected by BCAAs. Even those considered "obese, metabolically well" had metabolite levels which significantly trended towards those found in obese diabetics. Overall, this analysis yields a more granular view of metabolic wellness than the sole use of cardiometabolic MS parameters. This, in turn, suggests the possible utility of plasma metabolomic analysis for research and public health applications., Competing Interests: The authors declare there are no competing interests.
- Published
- 2018
- Full Text
- View/download PDF
20. A hypomorphic inherited pathogenic variant in DDX3X causes male intellectual disability with additional neurodevelopmental and neurodegenerative features.
- Author
-
Kellaris G, Khan K, Baig SM, Tsai IC, Zamora FM, Ruggieri P, Natowicz MR, and Katsanis N
- Subjects
- Adolescent, Adult, Alleles, Chromosomes, Human, X genetics, Exome genetics, Female, Humans, Intellectual Disability physiopathology, Male, Mutation, Neurodegenerative Diseases physiopathology, Neurodevelopmental Disorders physiopathology, Pedigree, Exome Sequencing, Young Adult, DEAD-box RNA Helicases genetics, Intellectual Disability genetics, Neurodegenerative Diseases genetics, Neurodevelopmental Disorders genetics
- Abstract
Background: Intellectual disability (ID) is a common condition with a population prevalence frequency of 1-3% and an enrichment for males, driven in part by the contribution of mutant alleles on the X-chromosome. Among the more than 500 genes associated with ID, DDX3X represents an outlier in sex specificity. Nearly all reported pathogenic variants of DDX3X are de novo, affect mostly females, and appear to be loss of function variants, consistent with the hypothesis that haploinsufficiency at this locus on the X-chromosome is likely to be lethal in males., Results: We evaluated two male siblings with syndromic features characterized by mild-to-moderate ID and progressive spasticity. Quad-based whole-exome sequencing revealed a maternally inherited missense variant encoding p.R79K in DDX3X in both siblings and no other apparent pathogenic variants. We assessed its possible relevance to their phenotype using an established functional assay for DDX3X activity in zebrafish embryos and found that this allele causes a partial loss of DDX3X function and thus represents a hypomorphic variant., Conclusions: Our genetic and functional data suggest that partial loss of function of DDX3X can cause syndromic ID. The p.R79K allele affects a region of the protein outside the critical RNA helicase domain, offering a credible explanation for the observed retention of partial function, viability in hemizygous males, and lack of pathology in females. These findings expand the gender spectrum of pathology of this locus and suggest that analysis for DDX3X variants should be considered relevant for both males and females.
- Published
- 2018
- Full Text
- View/download PDF
21. Proteomic explorations of autism spectrum disorder.
- Author
-
Szoko N, McShane AJ, and Natowicz MR
- Subjects
- Animals, Autism Spectrum Disorder genetics, Brain metabolism, Humans, Proteins metabolism, Autism Spectrum Disorder metabolism, Proteomics methods
- Abstract
Proteomics, the large-scale study of protein expression in cells and tissues, is a powerful tool to study the biology of clinical conditions and has provided significant insights in many experimental systems. Herein, we review the basics of proteomic methodology and discuss challenges in using proteomic approaches to study autism. Unlike other experimental approaches, such as genomic approaches, there have been few large-scale studies of proteins in tissues from persons with autism. Most of the proteomic studies on autism used blood or other peripheral tissues; few studies used brain tissue. Some studies found dysregulation of aspects of the immune system or of aspects of lipid metabolism, but no consistent findings were noted. Based on the challenges in using proteomics to study autism, we discuss considerations for future studies. Apart from the complex technical considerations implicit in any proteomic analysis, key nontechnical matters include attention to subject and specimen inclusion/exclusion criteria, having adequate sample size to ensure appropriate powering of the study, attention to the state of specimens prior to proteomic analysis, and the use of a replicate set of specimens, when possible. We conclude by discussing some potentially productive uses of proteomics, potentially coupled with other approaches, for future autism research including: (1) proteomic analysis of banked human brain specimens; (2) proteomic analysis of tissues from animal models of autism; and (3) proteomic analysis of induced pluripotent stem cells that are differentiated into various types of brain cells and neural organoids. Autism Res 2017, 10: 1460-1469. © 2017 International Society for Autism Research, Wiley Periodicals, Inc., (© 2017 International Society for Autism Research, Wiley Periodicals, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
22. A novel microduplication of ARID1B: Clinical, genetic, and proteomic findings.
- Author
-
Seabra CM, Szoko N, Erdin S, Ragavendran A, Stortchevoi A, Maciel P, Lundberg K, Schlatzer D, Smith J, Talkowski ME, Gusella JF, and Natowicz MR
- Subjects
- Abnormalities, Multiple, Adolescent, Developmental Disabilities physiopathology, Face physiopathology, Gene Duplication genetics, Hand Deformities, Congenital physiopathology, Haploinsufficiency genetics, Humans, In Situ Hybridization, Fluorescence, Intellectual Disability physiopathology, Male, Mutation, Proteomics, DNA-Binding Proteins genetics, Developmental Disabilities genetics, Hand Deformities, Congenital genetics, Intellectual Disability genetics, Transcription Factors genetics
- Abstract
Genetic alterations of ARID1B have been recently recognized as one of the most common mendelian causes of intellectual disability and are associated with both syndromic and non-syndromic phenotypes. The ARID1B protein, a subunit of the chromatin remodeling complex SWI/SNF-A, is involved in the regulation of transcription and multiple downstream cellular processes. We report here the clinical, genetic, and proteomic phenotypes of an individual with a unique apparent de novo mutation of ARID1B due to an intragenic duplication. His neurodevelopmental phenotype includes a severe speech/language disorder with full scale IQ scores 78-98 and scattered academic skill levels, expanding the phenotypic spectrum of ARID1B mutations. Haploinsufficiency of ARID1B was determined both by RNA sequencing and quantitative RT-PCR. Fluorescence in situ hybridization analysis supported an intragenic localization of the ARID1B copy number gain. Principal component analysis revealed marked differentiation of the subject's lymphoblast proteome from that of controls. Of 3426 proteins quantified, 1014 were significantly up- or down-regulated compared to controls (q < 0.01). Pathway analysis revealed highly significant enrichment for canonical pathways of EIF2 and EIF4 signaling, protein ubiquitination, tRNA charging and chromosomal replication, among others. Network analyses revealed down-regulation of: (1) intracellular components involved in organization of membranes, organelles, and vesicles; (2) aspects of cell cycle control, signal transduction, and nuclear protein export; (3) ubiquitination and proteosomal function; and (4) aspects of mRNA synthesis/splicing. Further studies are needed to determine the detailed molecular and cellular mechanisms by which constitutional haploinsufficiency of ARID1B causes syndromic and non-syndromic developmental disabilities., (© 2017 Wiley Periodicals, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
23. Investigations of blood ammonia analysis: Test matrices, storage, and stability.
- Author
-
Goldstein BN, Wesler J, Nowacki AS, Reineks E, and Natowicz MR
- Subjects
- Adult, Anticoagulants chemistry, Edetic Acid chemistry, Heparin chemistry, Humans, Male, Oxalates chemistry, Time Factors, Ammonia blood, Blood Preservation, Cryopreservation
- Abstract
An assessment of blood ammonia concentration is common medical practice in the evaluation of an individual with an unexplained mental status change or coma. The determination of a blood ammonia level is most commonly done using a glutamate dehydrogenase (GLDH)-based assay, although there are many potential sources of artifact and the literature is inconsistent regarding key preanalytic issues. Using a GLDH-based assay, we first investigated matrix effects using three anticoagulants: heparin, EDTA and oxalate. Heparin-anticoagulated plasma was substantially less precise than EDTA- and oxalate-anticoagulated plasma. Oxalate-anticoagulated plasma showed a greater baseline of apparent ammonia than either heparin- or EDTA-derived plasma, presumably due to interferants. We then evaluated the stability of EDTA-anticoagulated plasma for assessment of ammonia when stored at 4°C,-14°C or -70°C. There was a linear increase of ammonia with storage at both 4°C and -14°C. Plasma kept at -70°C for up to three weeks showed no change in measured ammonia relative to the baseline determination. This work clarifies preanalytic conditions for which a precise determination of ammonia can be accomplished using a GLDH-based assay., (Copyright © 2017 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
24. Early Identification and Interventions for Autism Spectrum Disorder: Executive Summary.
- Author
-
Zwaigenbaum L, Bauman ML, Choueiri R, Fein D, Kasari C, Pierce K, Stone WL, Yirmiya N, Estes A, Hansen RL, McPartland JC, Natowicz MR, Buie T, Carter A, Davis PA, Granpeesheh D, Mailloux Z, Newschaffer C, Robins D, Smith Roley S, Wagner S, and Wetherby A
- Subjects
- Academies and Institutes organization & administration, Autism Spectrum Disorder therapy, Child, Preschool, Humans, Infant, Pediatrics organization & administration, Practice Guidelines as Topic standards, United States, Autism Spectrum Disorder diagnosis
- Published
- 2015
- Full Text
- View/download PDF
25. Early Intervention for Children With Autism Spectrum Disorder Under 3 Years of Age: Recommendations for Practice and Research.
- Author
-
Zwaigenbaum L, Bauman ML, Choueiri R, Kasari C, Carter A, Granpeesheh D, Mailloux Z, Smith Roley S, Wagner S, Fein D, Pierce K, Buie T, Davis PA, Newschaffer C, Robins D, Wetherby A, Stone WL, Yirmiya N, Estes A, Hansen RL, McPartland JC, and Natowicz MR
- Subjects
- Autism Spectrum Disorder diagnosis, Biomedical Research, Child, Preschool, Humans, Infant, Parents education, Autism Spectrum Disorder therapy, Early Medical Intervention methods
- Abstract
This article reviews current evidence for autism spectrum disorder (ASD) interventions for children aged <3 years, based on peer-reviewed articles published up to December 2013. Several groups have adapted treatments initially designed for older, preschool-aged children with ASD, integrating best practice in behavioral teaching methods into a developmental framework based on current scientific understanding of how infants and toddlers learn. The central role of parents has been emphasized, and interventions are designed to incorporate learning opportunities into everyday activities, capitalize on "teachable moments," and facilitate the generalization of skills beyond the familiar home setting. Our review identified several comprehensive and targeted treatment models with evidence of clear benefits. Although some trials were limited to 8- to 12-week outcome data, enhanced outcomes associated with some interventions were evaluated over periods as long as 2 years. Based on this review, recommendations are proposed for clinical practice and future research., (Copyright © 2015 by the American Academy of Pediatrics.)
- Published
- 2015
- Full Text
- View/download PDF
26. Early Screening of Autism Spectrum Disorder: Recommendations for Practice and Research.
- Author
-
Zwaigenbaum L, Bauman ML, Fein D, Pierce K, Buie T, Davis PA, Newschaffer C, Robins DL, Wetherby A, Choueiri R, Kasari C, Stone WL, Yirmiya N, Estes A, Hansen RL, McPartland JC, Natowicz MR, Carter A, Granpeesheh D, Mailloux Z, Smith Roley S, and Wagner S
- Subjects
- Biomarkers, Child, Preschool, Early Diagnosis, Humans, Infant, Autism Spectrum Disorder diagnosis, Biomedical Research, Mass Screening methods
- Abstract
This article reviews current evidence for autism spectrum disorder (ASD) screening based on peer-reviewed articles published to December 2013. Screening provides a standardized process to ensure that children are systematically monitored for early signs of ASD to promote earlier diagnosis. The current review indicates that screening in children aged 18 to 24 months can assist in early detection, consistent with current American Academy of Pediatrics' recommendations. We identify ASD-specific and broadband screening tools that have been evaluated in large community samples which show particular promise in terms of accurate classification and clinical utility. We also suggest strategies to help overcome challenges to implementing ASD screening in community practice, as well as priorities for future research., (Copyright © 2015 by the American Academy of Pediatrics.)
- Published
- 2015
- Full Text
- View/download PDF
27. Early Identification of Autism Spectrum Disorder: Recommendations for Practice and Research.
- Author
-
Zwaigenbaum L, Bauman ML, Stone WL, Yirmiya N, Estes A, Hansen RL, McPartland JC, Natowicz MR, Choueiri R, Fein D, Kasari C, Pierce K, Buie T, Carter A, Davis PA, Granpeesheh D, Mailloux Z, Newschaffer C, Robins D, Roley SS, Wagner S, and Wetherby A
- Subjects
- Biomarkers, Child, Preschool, Early Diagnosis, Humans, Infant, Risk Assessment, Autism Spectrum Disorder diagnosis, Biomedical Research
- Abstract
Early identification of autism spectrum disorder (ASD) is essential to ensure that children can access specialized evidence-based interventions that can help to optimize long-term outcomes. Early identification also helps shorten the stressful "diagnostic odyssey" that many families experience before diagnosis. There have been important advances in research into the early development of ASDs, incorporating prospective designs and new technologies aimed at more precisely delineating the early emergence of ASD. Thus, an updated review of the state of the science of early identification of ASD was needed to inform best practice. These issues were the focus of a multidisciplinary panel of clinical practitioners and researchers who completed a literature review and reached consensus on current evidence addressing the question "What are the earliest signs and symptoms of ASD in children aged ≤24 months that can be used for early identification?" Summary statements address current knowledge on early signs of ASD, potential contributions and limitations of prospective research with high-risk infants, and priorities for promoting the incorporation of this knowledge into clinical practice and future research., (Copyright © 2015 by the American Academy of Pediatrics.)
- Published
- 2015
- Full Text
- View/download PDF
28. Biology of hyaluronan: Insights from genetic disorders of hyaluronan metabolism.
- Author
-
Triggs-Raine B and Natowicz MR
- Abstract
Hyaluronan is a rapidly turned over component of the vertebrate extracellular matrix. Its levels are determined, in part, by the hyaluronan synthases, HAS1, HAS2, and HAS3, and three hyaluronidases, HYAL1, HYAL2 and HYAL3. Hyaluronan binding proteins also regulate hyaluronan levels although their involvement is less well understood. To date, two genetic disorders of hyaluronan metabolism have been reported in humans: HYAL1 deficiency (Mucopolysaccharidosis IX) in four individuals with joint pathology as the predominant phenotypic finding and HAS2 deficiency in a single person having cardiac pathology. However, inherited disorders and induced mutations affecting hyaluronan metabolism have been characterized in other species. Overproduction of hyaluronan by HAS2 results in skin folding and thickening in shar-pei dogs and the naked mole rat, whereas a complete deficiency of HAS2 causes embryonic lethality in mice due to cardiac defects. Deficiencies of murine HAS1 and HAS3 result in a predisposition to seizures. Like humans, mice with HYAL1 deficiency exhibit joint pathology. Mice lacking HYAL2 have variably penetrant developmental defects, including skeletal and cardiac anomalies. Thus, based on mutant animal models, a partial deficiency of HAS2 or HYAL2 might be compatible with survival in humans, while complete deficiencies of HAS1, HAS3, and HYAL3 may yet be recognized.
- Published
- 2015
- Full Text
- View/download PDF
29. Dravet syndrome patient-derived neurons suggest a novel epilepsy mechanism.
- Author
-
Liu Y, Lopez-Santiago LF, Yuan Y, Jones JM, Zhang H, O'Malley HA, Patino GA, O'Brien JE, Rusconi R, Gupta A, Thompson RC, Natowicz MR, Meisler MH, Isom LL, and Parent JM
- Subjects
- Cell Differentiation, Cells, Cultured, Child, Female, Fibroblasts physiology, Humans, Inhibitory Postsynaptic Potentials genetics, Male, Membrane Potentials, Patch-Clamp Techniques, Epilepsies, Myoclonic genetics, Epilepsies, Myoclonic pathology, Mutation genetics, NAV1.1 Voltage-Gated Sodium Channel genetics, Neurons physiology
- Abstract
Objective: Neuronal channelopathies cause brain disorders, including epilepsy, migraine, and ataxia. Despite the development of mouse models, pathophysiological mechanisms for these disorders remain uncertain. One particularly devastating channelopathy is Dravet syndrome (DS), a severe childhood epilepsy typically caused by de novo dominant mutations in the SCN1A gene encoding the voltage-gated sodium channel Na(v) 1.1. Heterologous expression of mutant channels suggests loss of function, raising the quandary of how loss of sodium channels underlying action potentials produces hyperexcitability. Mouse model studies suggest that decreased Na(v) 1.1 function in interneurons causes disinhibition. We aim to determine how mutant SCN1A affects human neurons using the induced pluripotent stem cell (iPSC) method to generate patient-specific neurons., Methods: Here we derive forebrain-like pyramidal- and bipolar-shaped neurons from 2 DS subjects and 3 human controls by iPSC reprogramming of fibroblasts. DS and control iPSC-derived neurons are compared using whole-cell patch clamp recordings. Sodium current density and intrinsic neuronal excitability are examined., Results: Neural progenitors from DS and human control iPSCs display a forebrain identity and differentiate into bipolar- and pyramidal-shaped neurons. DS patient-derived neurons show increased sodium currents in both bipolar- and pyramidal-shaped neurons. Consistent with increased sodium currents, both types of patient-derived neurons show spontaneous bursting and other evidence of hyperexcitability. Sodium channel transcripts are not elevated, consistent with a post-translational mechanism., Interpretation: These data demonstrate that epilepsy patient-specific iPSC-derived neurons are useful for modeling epileptic-like hyperactivity. Our findings reveal a previously unrecognized cell-autonomous epilepsy mechanism potentially underlying DS, and offer a platform for screening new antiepileptic therapies., (© 2013 American Neurological Association.)
- Published
- 2013
- Full Text
- View/download PDF
30. Cerebrospinal fluid lactate and pyruvate concentrations and their ratio.
- Author
-
Zhang WM and Natowicz MR
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, Reference Values, Lactic Acid cerebrospinal fluid, Pyruvic Acid cerebrospinal fluid
- Abstract
Objectives: Determinations of cerebrospinal fluid (CSF) lactate and pyruvate concentrations and CSF lactate:pyruvate (L/P) ratios are important in several clinical settings, yet published normative data have significant limitations. We sought to determine a large dataset of stringently-defined normative data for CSF lactate and pyruvate concentrations and CSF L/P ratios., Design and Methods: We evaluated data from 627 patients who had determinations of CSF lactate and/or CSF pyruvate from 2001 to 2011 at the Cleveland Clinic. Inclusion in the normal reference population required normal CSF cell counts, glucose and protein and routine serum chemistries and absence of progressive brain disorder, epilepsy, or seizure within 24h. Brain MRI, if done, showed no evidence of tumor, acute changes or basal ganglia abnormality. CSF cytology, CSF alanine and immunoglobulin levels, and oligoclonal band analysis were required to be normal, if done. Various inclusion/exclusion criteria were compared., Results: 92 patients fulfilled inclusion/exclusion criteria for a reference population. The 95% central intervals (2.5%-97.5%) for CSF lactate and pyruvate levels were 1.01-2.09mM and 0.03-0.15mM, respectively, and 9.05-26.37 for CSF L/P. There were no significant gender-related differences of CSF lactate or pyruvate concentrations or of CSF L/P. Weak positive correlations between the concentration of CSF lactate or pyruvate and age were noted., Conclusions: Using stringent inclusion/exclusion criteria, we determined normative data for CSF lactate and pyruvate concentrations and CSF L/P ratios in a large, well-characterized reference population. Normalcy of routine CSF and blood analytes are the most important parameters in determining reference intervals for CSF lactate and pyruvate., (Copyright © 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
31. New NBIA subtype: genetic, clinical, pathologic, and radiographic features of MPAN.
- Author
-
Hogarth P, Gregory A, Kruer MC, Sanford L, Wagoner W, Natowicz MR, Egel RT, Subramony SH, Goldman JG, Berry-Kravis E, Foulds NC, Hammans SR, Desguerre I, Rodriguez D, Wilson C, Diedrich A, Green S, Tran H, Reese L, Woltjer RL, and Hayflick SJ
- Subjects
- Adolescent, Adult, Brain Chemistry genetics, Child, Child, Preschool, Cohort Studies, DNA genetics, Dystonia etiology, Electroencephalography, Electromyography, Fecal Incontinence etiology, Female, Gait Disorders, Neurologic etiology, Humans, Immunohistochemistry, Iron Overload diagnostic imaging, Iron Overload pathology, Lewy Body Disease pathology, Male, Mitochondrial Proteins genetics, Mutation, Neurodegenerative Diseases complications, Neurodegenerative Diseases diagnostic imaging, Neurologic Examination, Phenotype, Radiography, Urinary Incontinence etiology, Young Adult, Iron Overload genetics, Neurodegenerative Diseases genetics, Neurodegenerative Diseases pathology
- Abstract
Objective: To assess the frequency of mutations in C19orf12 in the greater neurodegeneration with brain iron accumulation (NBIA) population and further characterize the associated phenotype., Methods: Samples from 161 individuals with idiopathic NBIA were screened, and C19orf12 mutations were identified in 23 subjects. Direct examinations were completed on 8 of these individuals, and medical records were reviewed on all 23. Histochemical and immunohistochemical studies were performed on brain tissue from one deceased subject., Results: A variety of mutations were detected in this cohort, in addition to the Eastern European founder mutation described previously. The characteristic clinical features of mitochondrial membrane protein-associated neurodegeneration (MPAN) across all age groups include cognitive decline progressing to dementia, prominent neuropsychiatric abnormalities, and a motor neuronopathy. A distinctive pattern of brain iron accumulation is universal. Neuropathologic studies revealed neuronal loss, widespread iron deposits, and eosinophilic spheroidal structures in the basal ganglia. Lewy neurites were present in the globus pallidus, and Lewy bodies and neurites were widespread in other areas of the corpus striatum and midbrain structures., Conclusions: MPAN is caused by mutations in C19orf12 leading to NBIA and prominent, widespread Lewy body pathology. The clinical phenotype is recognizable and distinctive, and joins pantothenate kinase-associated neurodegeneration and PLA2G6-associated neurodegeneration as one of the major forms of NBIA.
- Published
- 2013
- Full Text
- View/download PDF
32. Patterning of regional gene expression in autism: new complexity.
- Author
-
Ginsberg MR, Rubin RA, and Natowicz MR
- Subjects
- Brain pathology, Case-Control Studies, Cerebellum metabolism, Cerebellum pathology, Cerebral Cortex pathology, Computational Biology, Frontal Lobe pathology, Humans, Oligonucleotide Array Sequence Analysis, RNA, Messenger genetics, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, Temporal Lobe pathology, Autistic Disorder genetics, Biomarkers metabolism, Brain metabolism, Cerebral Cortex metabolism, Frontal Lobe metabolism, Gene Expression Profiling, Temporal Lobe metabolism
- Abstract
Autism is a common and often severe neurodevelopmental disorder for which diverse pathophysiological processes have been proposed. Recent gene expression data comparing autistic and control brains suggest that the normal differential gene expression between frontal and temporal cortex is attenuated in autistic brains. It is unknown if regional de-differentiation occurs elsewhere in autistic brain. Using high resolution, genome-wide RNA expression microarrays and brain specimens meeting stringent selection criteria we evaluated gene expression data of two other regions: Brodmann area 19 (occipital cortex) and cerebellar cortex. In contrast to frontal/temporal cortical data, our data do not indicate an attenuation of regional specialization between occipital and cerebellar cortical regions in autistic brains.
- Published
- 2013
- Full Text
- View/download PDF
33. Disruption of a large intergenic noncoding RNA in subjects with neurodevelopmental disabilities.
- Author
-
Talkowski ME, Maussion G, Crapper L, Rosenfeld JA, Blumenthal I, Hanscom C, Chiang C, Lindgren A, Pereira S, Ruderfer D, Diallo AB, Lopez JP, Turecki G, Chen ES, Gigek C, Harris DJ, Lip V, An Y, Biagioli M, Macdonald ME, Lin M, Haggarty SJ, Sklar P, Purcell S, Kellis M, Schwartz S, Shaffer LG, Natowicz MR, Shen Y, Morton CC, Gusella JF, and Ernst C
- Subjects
- Adolescent, Alternative Splicing, Base Sequence, Chromosome Breakpoints, Chromosomes, Human, Pair 11, Chromosomes, Human, Pair 2, Female, Gene Order, Humans, Lymphocytes metabolism, Molecular Sequence Data, Neural Stem Cells metabolism, Translocation, Genetic, Developmental Disabilities genetics, Mutation, RNA, Long Noncoding genetics
- Abstract
Large intergenic noncoding (linc) RNAs represent a newly described class of ribonucleic acid whose importance in human disease remains undefined. We identified a severely developmentally delayed 16-year-old female with karyotype 46,XX,t(2;11)(p25.1;p15.1)dn in the absence of clinically significant copy number variants (CNVs). DNA capture followed by next-generation sequencing of the translocation breakpoints revealed disruption of a single noncoding gene on chromosome 2, LINC00299, whose RNA product is expressed in all tissues measured, but most abundantly in brain. Among a series of additional, unrelated subjects referred for clinical diagnostic testing who showed CNV affecting this locus, we identified four with exon-crossing deletions in association with neurodevelopmental abnormalities. No disruption of the LINC00299 coding sequence was seen in almost 14,000 control subjects. Together, these subjects with disruption of LINC00299 implicate this particular noncoding RNA in brain development and raise the possibility that, as a class, abnormalities of lincRNAs may play a significant role in human developmental disorders., (Copyright © 2012 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
34. The adult polyglucosan body disease mutation GBE1 c.1076A>C occurs at high frequency in persons of Ashkenazi Jewish background.
- Author
-
Hussain A, Armistead J, Gushulak L, Kruck C, Pind S, Triggs-Raine B, and Natowicz MR
- Subjects
- Gene Frequency, Humans, Mutation, beta-Hexosaminidase alpha Chain genetics, Glycogen Debranching Enzyme System genetics, Glycogen Storage Disease genetics, Jews genetics, Nervous System Diseases genetics
- Abstract
Mutations of the glycogen branching enzyme gene, GBE1, result in glycogen storage disease (GSD) type IV, an autosomal recessive disorder having multiple clinical forms. One mutant allele of this gene, GBE1 c.1076A>C, has been reported in Ashkenazi Jewish cases of an adult-onset form of GSD type IV, adult polyglucosan body disease (APBD), but no epidemiological analyses of this mutation have been performed. We report here the first epidemiological study of this mutation in persons of Ashkenazi Jewish background and find that this mutation has a gene frequency of 1 in 34.5 (95% CI: 0.0145-0.0512), similar to the frequency of the common mutation causing Tay-Sachs disease among Ashkenazi Jews. This finding reveals APBD to be another monogenic disorder that occurs with increased frequency in persons of Ashkenazi Jewish ancestry., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
35. Adult polyglucosan body disease: Natural History and Key Magnetic Resonance Imaging Findings.
- Author
-
Mochel F, Schiffmann R, Steenweg ME, Akman HO, Wallace M, Sedel F, Laforêt P, Levy R, Powers JM, Demeret S, Maisonobe T, Froissart R, Da Nobrega BB, Fogel BL, Natowicz MR, Lubetzki C, Durr A, Brice A, Rosenmann H, Barash V, Kakhlon O, Gomori JM, van der Knaap MS, and Lossos A
- Subjects
- 1,4-alpha-Glucan Branching Enzyme genetics, 1,4-alpha-Glucan Branching Enzyme metabolism, Adult, Aged, Cerebral Cortex pathology, Female, France, Humans, Israel, Kaplan-Meier Estimate, Male, Middle Aged, Mutation genetics, Netherlands, Neurologic Examination, Spinal Cord pathology, United States, Glycogen Storage Disease genetics, Glycogen Storage Disease pathology, Glycogen Storage Disease physiopathology, Magnetic Resonance Imaging, Nervous System Diseases genetics, Nervous System Diseases pathology, Nervous System Diseases physiopathology
- Abstract
Objective: Adult polyglucosan body disease (APBD) is an autosomal recessive leukodystrophy characterized by neurogenic bladder, progressive spastic gait, and peripheral neuropathy. Polyglucosan bodies accumulate in the central and peripheral nervous systems and are often associated with glycogen branching enzyme (GBE) deficiency. To improve clinical diagnosis and enable future evaluation of therapeutic strategies, we conducted a multinational study of the natural history and imaging features of APBD., Methods: We gathered clinical, biochemical, and molecular findings in 50 APBD patients with GBE deficiency from Israel, the United States, France, and the Netherlands. Brain and spine magnetic resonance images were reviewed in 44 patients., Results: The most common clinical findings were neurogenic bladder (100%), spastic paraplegia with vibration loss (90%), and axonal neuropathy (90%). The median age was 51 years for the onset of neurogenic bladder symptoms, 63 years for wheelchair dependence, and 70 years for death. As the disease progressed, mild cognitive decline may have affected up to half of the patients. Neuroimaging showed hyperintense white matter abnormalities on T2 and fluid attenuated inversion recovery sequences predominantly in the periventricular regions, the posterior limb of the internal capsule, the external capsule, and the pyramidal tracts and medial lemniscus of the pons and medulla. Atrophy of the medulla and spine was universal. p.Y329S was the most common GBE1 mutation, present as a single heterozygous (28%) or homozygous (48%) mutation., Interpretation: APBD with GBE deficiency, with occasional exceptions, is a clinically homogenous disorder that should be suspected in patients with adult onset leukodystrophy or spastic paraplegia with early onset of urinary symptoms and spinal atrophy., (Copyright © 2012 American Neurological Association.)
- Published
- 2012
- Full Text
- View/download PDF
36. Brain transcriptional and epigenetic associations with autism.
- Author
-
Ginsberg MR, Rubin RA, Falcone T, Ting AH, and Natowicz MR
- Subjects
- Adolescent, Adult, Brain pathology, Child, Child, Preschool, DNA Methylation, Fragile X Syndrome genetics, Gene Dosage, Gene Expression Regulation, Humans, Infant, Inflammation, Male, Middle Aged, Mitochondria metabolism, Models, Statistical, Myelin Sheath metabolism, Oligonucleotide Array Sequence Analysis, Oxidative Phosphorylation, Phenotype, Protein Biosynthesis, Sequence Analysis, DNA, Signal Transduction, Autistic Disorder genetics, Epigenesis, Genetic, Transcription, Genetic
- Abstract
Background: Autism is a common neurodevelopmental syndrome. Numerous rare genetic etiologies are reported; most cases are idiopathic., Methodology/principal Findings: To uncover important gene dysregulation in autism we analyzed carefully selected idiopathic autistic and control cerebellar and BA19 (occipital) brain tissues using high resolution whole genome gene expression and whole genome DNA methylation microarrays. No changes in DNA methylation were identified in autistic brain but gene expression abnormalities in two areas of metabolism were apparent: down-regulation of genes of mitochondrial oxidative phosphorylation and of protein translation. We also found associations between specific behavioral domains of autism and specific brain gene expression modules related to myelin/myelination, inflammation/immune response and purinergic signaling., Conclusions/significance: This work highlights two largely unrecognized molecular pathophysiological themes in autism and suggests differing molecular bases for autism behavioral endophenotypes.
- Published
- 2012
- Full Text
- View/download PDF
37. The C. elegans hyaluronidase: a developmentally significant enzyme with chondroitin-degrading activity at both acidic and neutral pH.
- Author
-
Chatel A, Hemming R, Hobert J, Natowicz MR, Triggs-Raine B, and Merz DC
- Subjects
- Animals, Caenorhabditis elegans genetics, Caenorhabditis elegans metabolism, Caenorhabditis elegans physiology, Chondroitin genetics, Female, Genes, Reporter, Glycosaminoglycans genetics, Glycosaminoglycans metabolism, Green Fluorescent Proteins metabolism, Hyaluronoglucosaminidase genetics, Hydrogen-Ion Concentration, In Vitro Techniques, Morphogenesis genetics, Muscles metabolism, Muscles physiology, Mutation, Oviposition genetics, Oviposition physiology, Sensory Receptor Cells metabolism, Transgenes, Vulva metabolism, Vulva physiology, Chondroitin metabolism, Hyaluronoglucosaminidase metabolism
- Abstract
Mammalian hyaluronidases degrade hyaluronan and some structurally related glycosaminoglycans. We generated a deletion mutant in the Caenorhabditis elegans orthologue of mammalian hyaluronidase, hya-1. Mutant animals are viable and grossly normal, but exhibit defects in vulval morphogenesis and egg-laying and showed increased staining with alcian blue, consistent with an accumulation of glycosaminoglycan. A hya-1::GFP reporter was expressed in a restricted pattern in somatic tissues of the animal with strongest expression in the intestine, the PLM sensory neurons and the vulva. Total protein extracts from wild-type animals exhibited chondroitin-degrading but not hyaluronan-degrading activity. Chondroitinase activities were observed at both neutral and acidic pH conditions while both neutral and acidic activities were absent in extracts from hya-1 mutant strains. We also evaluated the function of oga-1, which encodes the C. elegans orthologue of MGEA-5, a protein with hyaluronan-degrading activity in vitro. oga-1 is expressed in muscles, vulval cells and the scavenger-like coelomocytes. An oga-1 mutant strain exhibited egg-laying and vulval defects similar to those of hya-1; chondroitinase activity was unaffected in this mutant., (Copyright © 2010 International Society of Matrix Biology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
38. Atypical, perhaps under-recognized? An unusual phenotype of Friedreich ataxia.
- Author
-
Diehl B, Lee MS, Reid JR, Nielsen CD, and Natowicz MR
- Subjects
- Adult, Blindness genetics, Blindness pathology, Brain pathology, Humans, Iron-Binding Proteins genetics, Iron-Binding Proteins metabolism, Male, Optic Nerve pathology, Frataxin, Blindness etiology, Friedreich Ataxia complications, Friedreich Ataxia genetics, Friedreich Ataxia physiopathology, Phenotype
- Abstract
Friedreich ataxia (FRDA) is typically characterized by slowly progressive ataxia, depressed tendon reflexes, dysarthria, pyramidal signs, and loss of position and vibration sense with onset before 25 years. While several atypical forms of FRDA are recognized, profound vision deficit is rare. We describe here a 41-year-old man with profound vision deficit and episodic complete blindness associated with marked optic atrophy, spastic paraparesis, and sensory neuropathy without ataxia whose diagnostic evaluation revealed compound heterozygosity for two frataxin mutations, a 994 GAA repeat intronic expansion and c.389G > T (p.G130V) missense mutation. This case emphasizes that FRDA should be considered for individuals with significant vision deficit with optic atrophy and sensory neuropathy, even in the absence of ataxia. This case also raises the additional, related concern that prior studies may underestimate the frequency and varieties of variant forms of FRDA.
- Published
- 2010
- Full Text
- View/download PDF
39. Serum chitotriosidase activity and Wegener's granulomatosis.
- Author
-
Koening CL, Gota CE, Langford CA, Hoffman GS, and Natowicz MR
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Case-Control Studies, Demography, Female, Humans, Male, Middle Aged, Young Adult, Granulomatosis with Polyangiitis blood, Granulomatosis with Polyangiitis enzymology, Hexosaminidases blood
- Abstract
Objective: We evaluated serum chitotriosidase activity in patients with Wegener's granulomatosis (WG) and compared the values to controls., Design and Methods: We used a standard fluorometric assay to measure chitotriosidase enzyme activity., Results: Serum chitotriosidase enzyme activity levels were higher in WG patients. We found no association between clinical disease activity and chitotriosidase enzyme activity., Conclusions: Serum chitotriosidase enzyme activity has limited utility as a biomarker in WG patients., (Published by Elsevier Inc.)
- Published
- 2010
- Full Text
- View/download PDF
40. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report.
- Author
-
Buie T, Campbell DB, Fuchs GJ 3rd, Furuta GT, Levy J, Vandewater J, Whitaker AH, Atkins D, Bauman ML, Beaudet AL, Carr EG, Gershon MD, Hyman SL, Jirapinyo P, Jyonouchi H, Kooros K, Kushak R, Levitt P, Levy SE, Lewis JD, Murray KF, Natowicz MR, Sabra A, Wershil BK, Weston SC, Zeltzer L, and Winter H
- Subjects
- Caseins administration & dosage, Child, Child Behavior Disorders complications, Child Behavior Disorders etiology, Child Development Disorders, Pervasive immunology, Child Nutrition Disorders diagnosis, Child Nutrition Disorders etiology, Databases, Genetic, Diagnostic Techniques, Digestive System, Diet, Gluten-Free, Diet, Protein-Restricted, Food Hypersensitivity complications, Food Hypersensitivity diagnosis, Gastrointestinal Diseases complications, Gastrointestinal Diseases immunology, Gastrointestinal Tract physiology, Genetic Testing, Health Education, Health Personnel education, Humans, Intestines microbiology, Medical History Taking, Nutrition Assessment, Patient Care Team, Permeability, Practice Guidelines as Topic, Radiography, Abdominal, Child Development Disorders, Pervasive complications, Gastrointestinal Diseases diagnosis, Gastrointestinal Diseases therapy
- Abstract
Autism spectrum disorders (ASDs) are common and clinically heterogeneous neurodevelopmental disorders. Gastrointestinal disorders and associated symptoms are commonly reported in individuals with ASDs, but key issues such as the prevalence and best treatment of these conditions are incompletely understood. A central difficulty in recognizing and characterizing gastrointestinal dysfunction with ASDs is the communication difficulties experienced by many affected individuals. A multidisciplinary panel reviewed the medical literature with the aim of generating evidence-based recommendations for diagnostic evaluation and management of gastrointestinal problems in this patient population. The panel concluded that evidence-based recommendations are not yet available. The consensus expert opinion of the panel was that individuals with ASDs deserve the same thoroughness and standard of care in the diagnostic workup and treatment of gastrointestinal concerns as should occur for patients without ASDs. Care providers should be aware that problem behavior in patients with ASDs may be the primary or sole symptom of the underlying medical condition, including some gastrointestinal disorders. For these patients, integration of behavioral and medical care may be most beneficial. Priorities for future research are identified to advance our understanding and management of gastrointestinal disorders in persons with ASDs.
- Published
- 2010
- Full Text
- View/download PDF
41. On treatability: considerations of treatment in the context of newborn screening.
- Author
-
Natowicz MR and Zuckerman S
- Subjects
- Humans, Infant, Newborn, Decision Making, Neonatal Screening, Treatment Outcome
- Published
- 2009
42. Double outlet right ventricle: aetiologies and associations.
- Author
-
Obler D, Juraszek AL, Smoot LB, and Natowicz MR
- Subjects
- Animals, Chromosome Aberrations, Double Outlet Right Ventricle chemically induced, Double Outlet Right Ventricle embryology, Double Outlet Right Ventricle genetics, Humans, Teratogens toxicity, Double Outlet Right Ventricle etiology
- Abstract
Background: Double outlet right ventricle (DORV), a clinically significant congenital heart defect, occurs in 1-3% of individuals with congenital heart defects. In contrast to other major congenital heart defects, there are no systematic or comprehensive data regarding associations, aetiologies, and pathogenesis of DORV. We analysed reported cases in the medical literature to address these issues., Methods: We queried the PubMed database using key words "double outlet right ventricle" and "DORV" for case reports, epidemiologic analyses and animal studies with this cardiac anomaly. The anatomic subtype of DORV was classified according to criteria of Van Praagh., Results: Chromosomal abnormalities were present in 61 of the 149 cases of DORV. Trisomies 13 and 18, and del 22q11 were the most commonly associated cytogenetic lesions; different anatomic subtypes of DORV were noted in trisomies 13 and 18 versus del 22q11. DORV was reported in many uncommon or rare non-chromosomal syndromes. Mutations and non-synonymous sequence variants in the CFC1 and CSX genes were the most commonly reported monogenic loci associated with DORV in humans; numerous genes are reported in murine models of DORV. Animal studies implicate maternal diabetes and prenatal exposure to ethanol, retinoids, theophylline, and valproate in DORV teratogenesis., Conclusions: The large number of genes associated with DORV in both humans and animal models and the different anatomic subtypes seen in specific aetiologies indicate the likelihood of several distinct pathogenetic mechanisms for DORV, including impairment of neural crest derivative migration and impairment of normal cardiac situs and looping.
- Published
- 2008
- Full Text
- View/download PDF
43. Mitochondrial disease in autism spectrum disorder patients: a cohort analysis.
- Author
-
Weissman JR, Kelley RI, Bauman ML, Cohen BH, Murray KF, Mitchell RL, Kern RL, and Natowicz MR
- Subjects
- Adolescent, Autistic Disorder classification, Autistic Disorder diagnosis, Child, Child, Preschool, Cohort Studies, DNA, Mitochondrial genetics, Diagnosis, Differential, Electron Transport Complex I deficiency, Electron Transport Complex III deficiency, Female, Humans, Male, Mutation, Oxidative Phosphorylation, Phenotype, Young Adult, Autistic Disorder complications, Autistic Disorder etiology, Mitochondrial Diseases complications
- Abstract
Background: Previous reports indicate an association between autism spectrum disorders (ASD) and disorders of mitochondrial oxidative phosphorylation. One study suggested that children with both diagnoses are clinically indistinguishable from children with idiopathic autism. There are, however, no detailed analyses of the clinical and laboratory findings in a large cohort of these children. Therefore, we undertook a comprehensive review of patients with ASD and a mitochondrial disorder., Methodology/principal Findings: We reviewed medical records of 25 patients with a primary diagnosis of ASD by DSM-IV-TR criteria, later determined to have enzyme- or mutation-defined mitochondrial electron transport chain (ETC) dysfunction. Twenty-four of 25 patients had one or more major clinical abnormalities uncommon in idiopathic autism. Twenty-one patients had histories of significant non-neurological medical problems. Nineteen patients exhibited constitutional symptoms, especially excessive fatigability. Fifteen patients had abnormal neurological findings. Unusual developmental phenotypes included marked delay in early gross motor milestones (32%) and unusual patterns of regression (40%). Levels of blood lactate, plasma alanine, and serum ALT and/or AST were increased at least once in 76%, 36%, and 52% of patients, respectively. The most common ETC disorders were deficiencies of complex I (64%) and complex III (20%). Two patients had rare mtDNA mutations of likely pathogenicity., Conclusions/significance: Although all patients' initial diagnosis was idiopathic autism, careful clinical and biochemical assessment identified clinical findings that differentiated them from children with idiopathic autism. These and prior data suggest a disturbance of mitochondrial energy production as an underlying pathophysiological mechanism in a subset of individuals with autism.
- Published
- 2008
- Full Text
- View/download PDF
44. Plasma chitotriosidase in lysosomal storage diseases.
- Author
-
Isman F, Hobert JA, Thompson JN, and Natowicz MR
- Subjects
- Biomarkers blood, Humans, Lysosomal Storage Diseases blood, Hexosaminidases blood, Lysosomal Storage Diseases enzymology
- Published
- 2008
- Full Text
- View/download PDF
45. Access to health insurance: experiences and attitudes of those with genetic versus non-genetic medical conditions.
- Author
-
Kass NE, Medley AM, Natowicz MR, Hull SC, Faden RR, Plantinga L, and Gostin LO
- Subjects
- Adult, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Genetic Diseases, Inborn, Health Services Accessibility, Insurance, Health
- Abstract
While studies reveal that individuals with both genetic and other chronic medical conditions have difficulty obtaining health insurance, no large-scale studies have compared the health insurance experiences of these groups. The goal of this study was to document and compare the health insurance experiences, attitudes, and beliefs of persons with genetic conditions to those of persons with or at risk for other serious medical conditions. We interviewed approximately 100 adults or parents of children with one of each of the following medical conditions: sickle cell disease (SCD), cystic fibrosis (CF), diabetes, and HIV, and 200 adults with or at risk for breast (BC) or colon cancer (CC). The interview included items related to respondents' experiences and attitudes regarding health insurance. Twenty-seven percent of 597 total respondents self-reported having been denied health insurance or offered insurance at a prohibitive rate. Respondents with single-gene disorders (CF and SCD) were twice as likely to report this as those with non-genetic conditions. Legislation that exists to limit genetic discrimination in insurance addresses genetic risks or traits only, however, rather than protecting those with actual disease. Thus, current legislation may not address the challenges faced by individuals like those in this study, who try to maintain access to health insurance when they or their children are symptomatic with a genetic or other serious health condition. More than one-third of all respondents thought there was a high chance they would be denied health insurance in the future or their insurance would become unaffordable. That individuals with all six health conditions expressed concern regarding their ability to obtain future health insurance suggests policy proposals should be broad-based, addressing the needs and concerns of individuals with diverse health conditions.
- Published
- 2007
- Full Text
- View/download PDF
46. Evaluation of the risk for Tay-Sachs disease in individuals of French Canadian ancestry living in new England.
- Author
-
Martin DC, Mark BL, Triggs-Raine BL, and Natowicz MR
- Subjects
- Adult, Canada ethnology, Genetic Predisposition to Disease, Heterozygote, Humans, Massachusetts epidemiology, Mutation, Risk, beta-Hexosaminidase alpha Chain, beta-N-Acetylhexosaminidases genetics, Tay-Sachs Disease ethnology, Tay-Sachs Disease genetics, White People
- Abstract
Background: The assessment of risk for Tay-Sachs disease (TSD) in individuals of French Canadian background living in New England is an important health issue. In preliminary studies of the enzyme-defined carrier frequency for TSD among Franco-Americans in New England, we found frequencies (1:53) higher than predicted from the incidence of infantile TSD in this region. We have now further evaluated the risk for TSD in the Franco-American population of New England., Methods: Using a fluorescence-based assay for beta-hexosaminidase activity, we determined the carrier frequencies for TSD in 2783 Franco-Americans. DNA analysis was used to identify mutations causing enzyme deficiency in TSD carriers., Results: We determined the enzyme-defined carrier frequency for TSD as 1:65 (95% confidence interval 1:49 to 1:90). DNA-based analysis of 24 of the enzyme-defined carriers revealed 21 with sequence changes: 9 disease-causing, 4 benign, and 8 of unknown significance. Six of the unknowns were identified as c.748G>A p.G250S, a mutation we show by expression analysis to behave similarly to the previously described c.805G>A p.G269S adult-onset TSD mutation. This putative adult-onset TSD c.748G>A p.G250S mutation has a population frequency similar to the common 7.6 kb deletion mutation that occurs in persons of French Canadian ancestry., Conclusions: We estimate the frequency of deleterious TSD alleles in Franco-Americans to be 1:73 (95% confidence interval 1:55 to 1:107). These data provide a more complete data base from which to formulate policy recommendations regarding TSD heterozygosity screening in individuals of French Canadian background.
- Published
- 2007
- Full Text
- View/download PDF
47. Multiplex ligation-dependent probe amplification for rapid detection of proteolipid protein 1 gene duplications and deletions in affected males and carrier females with Pelizaeus-Merzbacher disease.
- Author
-
Warshawsky I, Chernova OB, Hübner CA, Stindl R, Henneke M, Gal A, and Natowicz MR
- Subjects
- Female, Gene Deletion, Gene Duplication, Humans, Male, Nucleic Acid Amplification Techniques, Oligonucleotide Probes, Reference Values, Carrier State, Membrane Proteins genetics, Myelin Proteolipid Protein genetics, Pelizaeus-Merzbacher Disease genetics
- Abstract
Background: Pelizaeus-Merzbacher disease is a rare X-linked neurodegenerative disorder caused by sequence variations in the proteolipid protein 1 gene (PLP1). PLP1 gene duplications account for approximately 50%-75% of cases and point variations for approximately 15%-20% of cases; deletions and insertions occur infrequently. We used multiplex ligation-dependent probe amplification (MLPA) to detect PLP1 gene alterations, especially gene duplications and deletions., Methods: We performed MLPA on 102 samples from individuals with diverse PLP1 gene abnormalities and from controls, including 50 samples previously characterized for the PLP1 gene by quantitative PCR but which were anonymized for prior results and sex., Results: All males with PLP1 gene duplications (n = 13), 1 male with a triplication, 2 males with whole gene deletions, and all controls (n = 72) were unambiguously assigned to their correct genotype. Of 4 female carriers tested by MLPA and quantitative PCR, 3 were duplication carriers by both methods, and 1 was a triplication carrier by MLPA and a duplication carrier by quantitative PCR. For 1 sample with a partial deletion, MLPA showed exon 3 deleted but PCR showed exons 3 and 4 deleted. Sequence analysis of 2 samples with reduced dosage for exons 3 and 5 revealed point variations overlapping the annealing site for the corresponding MLPA probe. The precision of MLPA analysis was excellent and comparable to or better than quantitative PCR, with CVs of 4.3%-9.8%., Conclusions: MLPA is a rapid and reliable method to determine PLP1 gene copies. Samples with partial PLP1 gene dosage alterations require confirmation with a non-MLPA method.
- Published
- 2006
- Full Text
- View/download PDF
48. Atypical GLUT1 deficiency with prominent movement disorder responsive to ketogenic diet.
- Author
-
Friedman JR, Thiele EA, Wang D, Levine KB, Cloherty EK, Pfeifer HH, De Vivo DC, Carruthers A, and Natowicz MR
- Subjects
- Athetosis diagnosis, Athetosis diet therapy, Athetosis genetics, Blood Glucose metabolism, Child, Chorea diagnosis, Chorea diet therapy, Chorea genetics, Developmental Disabilities diagnosis, Developmental Disabilities diet therapy, Erythrocyte Membrane metabolism, Genetic Carrier Screening, Glucose Transporter Type 1 genetics, Humans, Male, Microcephaly diagnosis, Microcephaly diet therapy, Movement Disorders diagnosis, Movement Disorders diet therapy, Mutagenesis, Insertional, Seizures diet therapy, Developmental Disabilities genetics, Dietary Fats administration & dosage, Glucose Transporter Type 1 deficiency, Microcephaly genetics, Movement Disorders genetics, Seizures genetics
- Abstract
Glucose transport protein deficiency due to mutation in the GLUT1 gene is characterized by infantile onset and chronic seizure disorder, microcephaly, global developmental delays, and hypoglycorrhachia. We describe a 10-year-old normocephalic male with prominent ataxia, dystonia, choreoathetosis, and GLUT1 deficiency whose motor abnormalities improved with a ketogenic diet. We illustrate the motor abnormalities, at baseline and after ketogenic diet, that characterize this unusual case. This case broadens the phenotype of GLUT1 deficiency and illustrates the importance of cerebrospinal fluid (CSF) evaluation in detecting potentially treatable conditions in children with undiagnosed movement disorders., (Copyright (c) 2005 Movement Disorder Society.)
- Published
- 2006
- Full Text
- View/download PDF
49. Lysosomal enzymes in human peripheral blood mononuclear cells and granulocytes.
- Author
-
Isman F, Palomaki GE, and Natowicz MR
- Subjects
- Adult, Humans, Granulocytes enzymology, Leukocytes, Mononuclear enzymology, Lysosomes enzymology
- Published
- 2005
- Full Text
- View/download PDF
50. Medical privacy and the disclosure of personal medical information: the beliefs and experiences of those with genetic and other clinical conditions.
- Author
-
Kass NE, Hull SC, Natowicz MR, Faden RR, Plantinga L, Gostin LO, and Slutsman J
- Subjects
- Adolescent, Adult, Confidentiality, Disclosure ethics, Employment ethics, Employment legislation & jurisprudence, Female, Humans, Insurance, Health ethics, Interviews as Topic, Male, Middle Aged, Prejudice, Privacy, Genetic Privacy ethics
- Abstract
There has been heightened legislative attention to medical privacy and to protections from genetic discrimination, without large-scale studies to document privacy concerns or analysis of whether experiences differ by whether the condition is genetic (defined here as a single-gene disorder) or non-genetic. To determine whether experiences regarding privacy, disclosure, and consequences of disclosure differ by whether one's medical condition is genetic, we conducted a descriptive study with one-time, structured quantitative and qualitative interviews. We interviewed approximately 100 adults or parents of children with each of the following medical conditions: sickle cell disease, cystic fibrosis, diabetes, and HIV, and 200 adults with or at risk for breast cancer or colon cancer. The percentages of the total 597 respondents experiencing positive or negative consequences of disclosure and the degree to which experiences differed by whether the condition was genetic were the outcomes of interest. Seventy-four percent were glad and 13% regretted others knew about their condition; these findings did not differ significantly by genetic vs. non-genetic condition. Reports of job and health insurance discrimination were not uncommon for the overall study population (19 and 27%, respectively) but were more likely among those with genetic conditions (30 and 37%, respectively). Legislation and other policy-making should target the needs of persons with all conditions and not focus exclusively on genetic discrimination, given that experiences and concerns generally do not differ based on the genetic etiology of the condition., (Copyright 2004 Wiley-Liss, Inc.)
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.